Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 11/20 | 0.68 |
| ▸ | EGFR | P00533 | 9/20 | 0.57 |
| ▸ | WEE1 | P30291 | 9/20 | 0.55 |
| ▸ | SRC | P12931 | 5/20 | 0.52 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.52 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.50 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.50 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.49 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.49 |
| ▸ | STAT5A | P42229 | 1/20 | 0.49 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.49 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16071791 | 0.91 | FGFR1 (0.59) | FGFR1EGFRWEE1SRCFGFR4 | |
| SCHEMBL15413005 | 0.87 | FGFR1 (0.52) | FGFR1EGFRWEE1FGFR4FGFR2 | |
| SCHEMBL15413093 | 0.86 | FGFR1 (0.72) | FGFR1EGFRWEE1SRCFGFR4 | |
| SCHEMBL19470190 | 0.86 | FGFR1 (0.52) | FGFR1EGFRFGFR4FGFR2FGFR3 | |
| SCHEMBL17925409 | 0.86 | FGFR1 (0.52) | FGFR1EGFRFGFR4FGFR2FGFR3 | |
| SCHEMBL15412848 | 0.85 | FGFR1 (0.65) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL15433999 | 0.85 | FGFR1 (0.58) | FGFR1SRCFGFR4FGFR2FGFR3 | |
| SCHEMBL19499689 | 0.84 | FGFR1 (0.51) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL19499703 | 0.83 | FGFR1 (0.49) | FGFR1FGFR4FGFR2FGFR3 | |
| SCHEMBL16071792 | 0.83 | FGFR1 (0.57) | FGFR1EGFRWEE1SRCFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2872491-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-2872491-B1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORP (US) | 2021-05-05 | — | — | EP | disclosed |
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180362613-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2018-12-20 | — | — | US | disclosed |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION | 2017-03-09 | — | — | US | disclosed |
| US-9340514-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-9340514-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2016-05-17 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802697-B2 | Inhibitors of the fibroblast growth factor receptor | BLUEPRINT MEDICINES CORPORATION (US) | 2014-08-12 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES CORPORATION (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-03-27 | — | — | US | disclosed |
| WO-2014011900-A2 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014011900-A2 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | BLUEPRINT MEDICINES (US) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196436-B2 | Inhibitors of the fibroblast growth factor receptor | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885EGFR 10/4885WEE1 649/4885 |
| US-20140088100-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885EGFR 10/4885WEE1 649/4885 |
| US-20170066812-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885EGFR 10/4885WEE1 649/4885 |
| US-20140187559-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885EGFR 10/4885WEE1 649/4885 |
| US-20180362613-A1 | INHIBITORS OF THE FIBROBLAST GROWTH FACTOR RECEPTOR | FGFR1, FGFR2, FGFR3 | FGFR1 1/4885EGFR 10/4885WEE1 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.